Dr. Ellinor was raised in Cincinnati and graduated summa cum laude from the University of Cincinnati with a degree in Biology. He then attended Stanford University for medical and graduate school. After completing doctoral work in the laboratory of Dr. Richard Tsien, he moved to Boston for medical residency at Brigham and Women’s Hospital. He then completed cardiology and cardiac electrophysiology fellowship training at Massachusetts General Hospital. Dr. Ellinor joined the staff of MGH in 2001, served as the Medical Director of the Cardiac Step-Down Unit for twelve years, and recently became the Director of the Cardiac Arrhythmia Service. He is an Associate Professor at Harvard Medical School and an Associate Member at the Broad Institute.
Dr. Ellinor’s research work has focused on identifying the molecular basis of atrial fibrillation. His research laboratories are located in the Cardiovascular Research Center at MGH and at the Broad Institute of Harvard and MIT. Dr. Ellinor currently helps to lead the AFGen Consortium, an international group of investigators studying the genetics of atrial fibrillation. Over the past 15 years, he has been continuously funded by the NIH, he has received an Established Investigator Award from the AHA, and he is a principal investigator on a Transatlantic Research Network sponsored by the Fondation Leducq. Dr. Ellinor also co-leads a unique academic industrial partnership between the Broad Institute and Bayer HealthCare focused on identifying novel therapeutic targets for myocardial infarction and atrial fibrillation. Dr. Ellinor is a member of the American Heart Association, the Heart Rhythm Society and the American Society of Clinical Investigation.